Literature DB >> 22129971

Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan.

Shih-Wei Lai1, Kuan-Fu Liao, Pei-Chun Chen, Pang-Yao Tsai, Dennis Paul Hsientang Hsieh, Ching-Chu Chen.   

Abstract

BACKGROUND: The risk of some forms of cancer has been found to be higher in patients with diabetes mellitus (DM) than in the general population. The aim of this study was to examine, with sufficient statistical power, the association between DM and lung cancer and the impact of antidiabetes drugs on lung cancer risk in Taiwan.
MATERIALS AND METHODS: From a randomly selected data set of 1 million National Health Insurance (NHI) claims in Taiwan from 2000-2005, 19,624 cases (patients ≥ 20 years of age) of newly diagnosed DM were identified. From the same data set, 78,496 enrollees with no record of DM were selected as controls and were matched in sex and age to the first group. The incidence of newly diagnosed lung cancer was compared between patients with DM and controls for a period of 9 years (2000-2008).
RESULTS: The multivariate Cox model analysis showed a slightly increased hazard ratio (HR) of 1.05 of lung cancer in patients with DM, but the association was not statistically significant. However the use of antidiabetes drugs, such as metformin, thiazolidinediones, or alpha-glucosidase inhibitors, correlates with a decreased lung cancer risk of 39%-45%. A significant association was found between lung cancer risk and male sex (HR, 2.23), pulmonary tuberculosis (HR, 1.60), chronic obstructive pulmonary disease (HR, 1.21), and age (HR, 1.07).
CONCLUSION: Patients with DM are not at increased risk for the development of lung cancer, but the use of antidiabetes drugs would considerably decrease the risk. In this cohort, male sex, age, pulmonary tuberculosis, and chronic obstructive pulmonary disease were all associated with an increased risk of lung cancer, consistent with findings in the literature and indicative of the validity of our study. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129971     DOI: 10.1016/j.cllc.2011.10.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  52 in total

1.  Metformin use and lung cancer risk in patients with diabetes.

Authors:  Lori C Sakoda; Assiamira Ferrara; Ninah S Achacoso; Tiffany Peng; Samantha F Ehrlich; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Prev Res (Phila)       Date:  2015-02

2.  Association of the metformin with the risk of lung cancer: a meta-analysis.

Authors:  Li Wang; Yong Song; Guan-Nan Wu; Dong-Mei Yuan
Journal:  Transl Lung Cancer Res       Date:  2013-08

Review 3.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

4.  Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.

Authors:  Su-Hsin Chang; Suhong Luo; Katiuscia K O'Brian; Theodore S Thomas; Graham A Colditz; Nils P Carlsson; Kenneth R Carson
Journal:  Lancet Haematol       Date:  2015-01       Impact factor: 18.959

Review 5.  Metformin and cancer.

Authors:  Natalia G Vallianou; Angelos Evangelopoulos; Christos Kazazis
Journal:  Rev Diabet Stud       Date:  2014-02-10

Review 6.  Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Authors:  Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-01

7.  Increased relative risk of acute pancreatitis in zolpidem users.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

Review 8.  Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.

Authors:  Ashish Saxena; Daniel Becker; Isabel Preeshagul; Karen Lee; Elena Katz; Benjamin Levy
Journal:  Oncologist       Date:  2015-07-08

Review 9.  Does Metformin Reduce Cancer Risks? Methodologic Considerations.

Authors:  Asieh Golozar; Shuiqing Liu; Joeseph A Lin; Kimberly Peairs; Hsin-Chieh Yeh
Journal:  Curr Diab Rep       Date:  2016-01       Impact factor: 4.810

Review 10.  Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Authors:  Cristina Bosetti; Valentina Rosato; Danilo Buniato; Antonella Zambon; Carlo La Vecchia; Giovanni Corrao
Journal:  Oncologist       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.